Clinical Trial Update: LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports on the efficacy of LIFEMEL in preventing hematopoietic toxicity (neutropenia) in patients undergoing chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• LIFEMEL

Snippet

Sponsor: VitalMel | Conditions: Neutropenia, Adverse Event | Phase 2 | Status: COMPLETED